Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
NCT02245230Phase 1Terminated
- Sponsor
- Vanderbilt University
- Start
- Jan 2015
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of angiotensin-(1-7) in essential hypertension (2 arms), sponsored by Vanderbilt University. Primary endpoint: Systolic Blood Pressure at 50 minutes. Started Jan 2015; status: terminated.
02
Drugs
angiotensin-(1-7)
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02245230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245230.